Biocon Biologics and Serum Institute Life Sciences partnership

INICIO/Noticias Farmacéuticas | Posted 12/11/2021 post-comment0 Post your comment

On 16 September 2021, a strategic partnership was announced between India-based biologicals specialist Biocon Biologics Limited (BBL), and Indian vaccine manufacturer Serum Institute Life Sciences (SILS), a subsidiary of Serum Institute of India Pvt Ltd.

64 MD002129

Under the terms of the partnership, SILS will have a 15% stake in BBL, valued at ~US$4.9 billion. In return, BBL will receive committed access to a 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune, India. BBL will also have commercialization rights to the SILS vaccine portfolio (including COVID-19 vaccines) for global markets.

The strategic partnership also plans to develop vaccines and antibodies targeting several infectious diseases, such as Dengue and HIV. Following development, the companies will enter service level agreements for manufacturing and distribution of the vaccines and antibodies.

This new partnership is one of many that Biocon has recently entered with organizations across the globe, such as the recently announced partnerships with Libbs to facilitate the sale of generics in Brazil [1], and with international organizations to improve access to cancer and diabetes treatments [2].

Furthermore, Biocon/Viatris’ insulin glargine biosimilar Semglee (insulin glargine-yfgn) has been approved by the US Food and Drug Administration as the first interchangeable biosimilar product approved in the US for the treatment of diabetes [3] in July 2021, which has been listed by Express Scripts, America’s largest pharmacy benefit management organization, as a preferred insulin brand on its National Preferred Formulary (NPF), which includes more than 28 million lives in the US [4].

Related articles
EC approves bevacizumab biosimilar Abevmy 

EC approval for insulin aspart biosimilar Kixelle

Biocon and Lupin launch generic tacrolimus capsules in US

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. Biocon partners with Libbs for the sale of generics in Brazil [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/pharma-news/Biocon-partners-with-Libbs-for-the-sale-of-generics-in-Brazil
2. GaBI Online - Generics and Biosimilars Initiative. Biocon Biologics partners to improve global access to cancer treatments and insulin [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www:gabionline.net/pharma-news/Biocon-Biologics-partners-to-improve-global-access-to-cancer-treatments-and-insulin
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable insulin glargine biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/biosimilars/news/fda-approves-first-interchangeable-insulin-glargine-biosimilar
4. GaBI Online - Generics and Biosimilars Initiative. Interchangeable insulin glargine biosimilar preferred on express scripts [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/biosimilars/general/interchangeable-insulin-glargine-biosimilar-preferred-on-express-scripts

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
24 AA011041
INICIO/Noticias Farmacéuticas Posted 26/11/2021
Swiss Social Democrat’s for nationalization of Sandoz
28 MD002360
INICIO/Noticias Farmacéuticas Posted 19/11/2021
Ustekinumab biosimilars: new international biopharma agreements
Contract Tender V13H30
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Agreement to produce similar biotherapeutic product in Turkey
12 AA010179
INICIO/Noticias Farmacéuticas Posted 05/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010